KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Shares Outstanding (Diluted Average) (2009 - 2026)

Johnson & Johnson recorded quarterly Shares Outstanding (Diluted Average) of $2.4 billion in Q1 2026, up 0.65% quarter-over-quarter from $2.4 billion in Q4 2025, and up 0.88% year-over-year from $2.4 billion in Q1 2025.

Johnson & Johnson's Shares Outstanding (Diluted Average) history runs 18 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

  • In Q1 2026, Shares Outstanding (Diluted Average) rose 0.88% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $2.4 billion (up 0.88% YoY), while the FY2025 annual figure was $2.4 billion, changed 0.0% from the prior year.
  • Shares Outstanding (Diluted Average) came in at $2.4 billion for Q1 2026 at Johnson & Johnson, up from $2.4 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $2.7 billion in Q1 2022 to a low of $2.4 billion in Q2 2025.
  • A 5-year average of $2.5 billion and a median of $2.5 billion in 2023 frame the typical range for Shares Outstanding (Diluted Average).
  • Across the five-year window, Shares Outstanding (Diluted Average) fell 7.69% in 2024 and advanced 0.88% in 2026, its largest moves.
  • Johnson & Johnson's Shares Outstanding (Diluted Average) stood at $2.7 billion in 2022, then fell by 3.79% to $2.6 billion in 2023, then decreased by 5.12% to $2.4 billion in 2024, then changed by 0.0% to $2.4 billion in 2025, then advanced by 0.65% to $2.4 billion in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $2.4 billion, $2.4 billion, and $2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Diluted Avg.) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 1.65 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 895.90 Mn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 2.45 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 1.77 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 544.00 Mn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 1.25 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 5.73 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 2.45 Bn
Dec 28, 2025 2.43 Bn
Sep 28, 2025 2.42 Bn
Jun 29, 2025 2.42 Bn
Mar 30, 2025 2.42 Bn
Dec 29, 2024 2.43 Bn
Sep 29, 2024 2.43 Bn
Jun 30, 2024 2.43 Bn
Mar 31, 2024 2.43 Bn
Dec 31, 2023 2.56 Bn
Oct 1, 2023 2.55 Bn
Jul 2, 2023 2.63 Bn
Apr 2, 2023 2.61 Bn
Jan 1, 2023 2.66 Bn
Oct 2, 2022 2.66 Bn
Jul 3, 2022 2.67 Bn
Apr 3, 2022 2.67 Bn
Jan 2, 2022 2.67 Bn
Oct 3, 2021 2.67 Bn
Jul 4, 2021 2.67 Bn
Apr 4, 2021 2.67 Bn
Jan 3, 2021 2.67 Bn
Sep 27, 2020 2.67 Bn
Jun 28, 2020 2.67 Bn
Mar 29, 2020 2.67 Bn
Dec 29, 2019 2.68 Bn
Sep 29, 2019 2.69 Bn
Jun 30, 2019 2.70 Bn
Mar 31, 2019 2.70 Bn
Dec 30, 2018 2.73 Bn
Sep 30, 2018 2.73 Bn
Jul 1, 2018 2.72 Bn
Apr 1, 2018 2.73 Bn
Dec 31, 2017 2.75 Bn
Oct 1, 2017 2.74 Bn
Jul 2, 2017 2.75 Bn
Apr 2, 2017 2.75 Bn
Jan 1, 2017 2.79 Bn
Oct 2, 2016 2.80 Bn
Jul 3, 2016 2.79 Bn
Apr 3, 2016 2.80 Bn
Jan 3, 2016 2.81 Bn
Sep 27, 2015 2.81 Bn
Jun 28, 2015 2.81 Bn
Mar 29, 2015 2.83 Bn
Dec 28, 2014 2.86 Bn
Sep 28, 2014 2.87 Bn
Jun 29, 2014 2.88 Bn
Mar 30, 2014 2.87 Bn
Dec 29, 2013 2.88 Bn
Sep 29, 2013 2.88 Bn
Jun 30, 2013 2.88 Bn
Mar 31, 2013 2.86 Bn
Dec 30, 2012 2.81 Bn
Sep 30, 2012 2.82 Bn
Jul 1, 2012 2.80 Bn
Apr 1, 2012 2.77 Bn
Jan 1, 2012 2.78 Bn
Oct 2, 2011 2.78 Bn
Jul 3, 2011 2.78 Bn
Apr 3, 2011 2.77 Bn
Jan 2, 2011 2.79 Bn
Oct 3, 2010 2.79 Bn
Jul 4, 2010 2.80 Bn
Apr 4, 2010 2.80 Bn
Jan 3, 2010 2.79 Bn
Sep 27, 2009 2.79 Bn
Jun 28, 2009 2.79 Bn
Mar 29, 2009 2.79 Bn